There are currently 166 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448
Recruiting
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/07/2025
Locations: Research Site, La Jolla, California +70 locations
Conditions: Lung Cancer
Register for Updates
Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer
NCT06530615
Recruiting
This project will study and characterize Microplastic (MP) burden in the lungs of patients undergoing Bronchoalveolar Levage (BAL) in thoracic clinics at Moffitt.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Lung Cancer
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: Hoag Cancer Center, Irvine, California +73 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +2 locations
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT00001823
Recruiting
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042
Recruiting
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Illinois Cancer Care ( Site 0101), Peoria, Illinois +53 locations
Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Register for Updates
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987
Recruiting
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Florida Cancer Specialists, Sarasota, Florida +9 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma
Register for Updates
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT00451022
Recruiting
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Register for Updates
Study Assessing QBS72S For Treating Brain Metastases
NCT05305365
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Register for Updates
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT06685718
Recruiting
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of Colorado, Denver, Colorado +38 locations
Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
Register for Updates
Exercise as Maintenance Therapy in Advanced Lung Cancer
NCT06513663
Recruiting
The purpose of this study is to examine how a multimodality (having or using a variety of methods to do something) exercise intervention may improve survival, function, and quality of life in participants with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Indiana University Health Methodist Hospital, Indianapolis, Indiana +2 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Metastatic Lung Cancer
Register for Updates